Clinician's Brief: The Podcast podcast

Available Episodes

5 of 295

Combating Uremic Toxins with Dr. Summers
Ready to refine your approach to managing feline chronic kidney disease (CKD)? In this episode of Clinician’s Brief Partner Podcast, Dr. Beth asks Dr. Stacie Summers, DVM, PhD, DACVIM, to share her expert insights into the often-overlooked role of uremic toxins in feline CKD. Listen in as they discuss why uremic toxins matter, their impact on the systemic health of CKD patients, and evidence-based strategies for effective management.Sponsored by DechraContact us:[email protected] to find us:Cliniciansbrief.com/podcastsFacebook.com/clinciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostTaylor Argo - Producer & Project Manager, Brief StudioRandall Stupka - Podcast Production & Sound Editing
--------
27:27
Top 3 Recent Advances in Feline Diabetes Management with Dr. Jenkins
In this episode, host Alyssa Watson, DVM, welcomes Alyssa Jenkins, DVM, to talk about her recent Clinician’s Brief article, “Top 3 Recent Advances in Feline Diabetes Management.” Dr. Jenkins starts with a feline diabetes mellitus refresher, including the comparison between it and type I/type II diabetes in humans. She then details the major new things for diabetic cats: SGLT2 inhibitors, longer-acting insulins, and continuous glucose monitors.Resource:https://www.cliniciansbrief.com/article/diabetes-cats-insulin-blood-sugar-monitorContact:[email protected] To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist
--------
44:19
Special Episode: Will Spectrum of Care Get Me Sued?
More and more veterinary professionals are embracing a spectrum of care approach–that is, the philosophy that “best medicine” means the care that best fits the pet and family in front of us, even if it’s not the most advanced care available. But, how do we do that without feeling even more vulnerable to lawsuits, board complaints, and angry online reviews?In this special episode, host Katie Berlin, DVM, is joined by Beth Venit, VMD, MPH, DAVPM, Kate Boatright, VMD, and Sarah L. Babcock, DVM, JD, to address legal and regulatory concerns expressed by veterinary professionals in a discussion about spectrum of care. In most cases, communication, empathy, and concise but thorough recordkeeping are as essential as good medicine, and these three experts offer tips to help us all feel more comfortable with the options we offer. Guests: Beth Venit, VMD, MPH, DAVPM, Chief Veterinary Officer, American Association of Veterinary State Boards (AAVSB)Sarah J. Babcock, DVM, JD, President, Animal & Veterinary Legal Services, PLLCKate Boatright, VMD, veterinary author and speakerResources: AVMA’s list of veterinary state board websitesDr. Sarah’s CE courses on medical recordkeeping, ethics, controlled substances, and professional standards of careContact:[email protected] To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Katie Berlin, DVM - HostAlexis Ussery - Producer & Multimedia Specialist
--------
1:17:49
Stabilization of Cats With Urethral Obstruction Prior to Referral with Dr. Thomovsky
In this episode, host Alyssa Watson, DVM, welcomes back Elizabeth Thomovsky, DVM, MS, DACVECC, to discuss her recent Clinician’s Brief article, “Stabilization of Cats With Urethral Obstruction Prior to Referral.” Dr. Thomovsky highlights the importance of recognizing early signs of obstruction, performing prompt physical examinations, and managing associated electrolyte imbalances, including the emergency treatment of hyperkalemia. She also outlines effective analgesia protocols and emphasizes the value of tailored treatment plans and recurrence monitoring, sharing practical tips for general practitioners on the front lines of care.Resource:https://www.cliniciansbrief.com/article/cats-hyperkalemia-stabilization-cystocentesis-catheterContact:[email protected] To Find Us:Website: CliniciansBrief.com/PodcastsYouTube: Youtube.com/@clinicians_briefFacebook: Facebook.com/CliniciansBriefLinkedIn: LinkedIn.com/showcase/CliniciansBrief/Instagram: @Clinicians.BriefX: @CliniciansBriefThe Team:Alyssa Watson, DVM - HostAlexis Ussery - Producer & Multimedia Specialist
--------
50:51
How JAK Inhibitors Are Shaping Treatment of Canine Allergic Disease with Dr. Rosenberg
For the first time in more than a decade, a new Janus kinase (JAK) inhibitor has been approved for veterinary use in the United States. In this episode of Clinician’s Brief Partner Podcast, Dr. Beth invites dermatologist Dr. Andrew Rosenberg to share everything practitioners need to know when it comes to using JAK inhibitors in practice, from the benefits of having options within the drug class to the implications of the boxed warning for the new option.Sponsored by Elanco INDICATIONSZenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.IMPORTANT SAFETY INFORMATIONRead the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenreliaWARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease from modified live virus vaccines and inadequate immune response to any vaccine. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert .Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-2308 (2) Contact us:[email protected] to find us:Cliniciansbrief.com/podcastsFacebook.com/clinciansbriefTwitter: @cliniciansbriefInstagram: @clinicians.briefThe Team:Beth Molleson, DVM - HostSarah Pate - Producer & Project Manager, Brief StudioRandall Stupka - Podcast Production & Sound Editing
--------
42:30